m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00391)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
SFPQ
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Fat mass and obesity-associated protein (FTO) [ERASER]
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | In bladder cancer, the changes in m6A methylation level mainly appeared at 5' untranslated region (5' UTR) of MALAT1 and NOTCH1 transcripts, and at 3' UTR of CSNK2A2 and ITGA6 transcripts, responding to the overexpression of FTO. Splicing factor, proline- and glutamine-rich (SFPQ) could influence the FTO-mediated m6A RNA demethylation, eventually affecting the gene expression. | |||
Responsed Disease | Bladder cancer | ICD-11: 2C94 | ||
Pathway Response | Notch signaling pathway | hsa04330 | ||
Cell Process | Cell proliferation | |||
Cell invasion | ||||
Cell apoptosis | ||||
In-vitro Model | HT-1197 | Recurrent bladder carcinoma | Homo sapiens | CVCL_1291 |
HT-1376 | Bladder carcinoma | Homo sapiens | CVCL_1292 | |
In-vivo Model | BALB/cnu/nu mice (4-5 weeks old) were used for the xenograft experiment. The mice were randomly divided into 2 groups (n = 6 for each group) and injected with 5 × 106 HT-1197 cells in control group or FTO plasmid group, respectively. | |||
Bladder cancer [ICD-11: 2C94]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | In bladder cancer, the changes in m6A methylation level mainly appeared at 5' untranslated region (5' UTR) of MALAT1 and NOTCH1 transcripts, and at 3' UTR of CSNK2A2 and ITGA6 transcripts, responding to the overexpression of FTO. Splicing factor, proline- and glutamine-rich (SFPQ) could influence the FTO-mediated m6A RNA demethylation, eventually affecting the gene expression. | |||
Responsed Disease | Bladder cancer [ICD-11: 2C94] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Pathway Response | Notch signaling pathway | hsa04330 | ||
Cell Process | Cell proliferation | |||
Cell invasion | ||||
Cell apoptosis | ||||
In-vitro Model | HT-1197 | Recurrent bladder carcinoma | Homo sapiens | CVCL_1291 |
HT-1376 | Bladder carcinoma | Homo sapiens | CVCL_1292 | |
In-vivo Model | BALB/cnu/nu mice (4-5 weeks old) were used for the xenograft experiment. The mice were randomly divided into 2 groups (n = 6 for each group) and injected with 5 × 106 HT-1197 cells in control group or FTO plasmid group, respectively. | |||